CLL   

Questions discussed in this category



What VAF burden would be considered significant prognostically or for treatment decisions?

Does this data change your preferred first line treatment regimens when considering other options such as mAb combos, cytotoxic chemotherapy?

Is the non-inferiority margin of 1.429 sufficient, how was this selected? Is the open label (rather than blinded) study design of any concern? Is th...

Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...


Papers discussed in this category


The New England journal of medicine, 2018-03-22

Lancet Oncol, 2016 May 20

Lancet Oncol,

J Clin Oncol, 2021 Jul 26

The Lancet. Oncology, 2018-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-01

Blood,

Blood Adv, 2022 Jun 14

J Clin Oncol, 2021 Oct 07